The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons.
We examined the effect of the amino bisphosphonate alendronate, administered IV every 2 weeks at 0.05 and 0.25 mg/kg for 1 year, on bone loss and parameters related to bone metabolism in ovariectomized baboons. Relative to non-OVX animals, the OVX baboons experienced increased bone turnover, reflected in biochemical and histomorphometric measurements, and bone loss assessed by dual-beam absorptiometry in the lumbar spine, which was similar to changes observed in ovariectomized women. Alendronate treatment maintained all parameters of bone turnover at control (nonovariectomized) levels and prevented the bone loss in a dose-dependent manner. We concluded that ovariectomized baboons offer a suitable model for the bone changes observed in ovariectomized women and that these changes can be prevented by sustained administration of an appropriate dose of this aminobisphosphonate.
Thompson
D D
DD
Merck, Sharp and Dohme Research Laboratories, West Point, Pennsylvania.
Seedor
J G
JG
Quartuccio
H
H
Solomon
H
H
Fioravanti
C
C
Davidson
J
J
Klein
H
H
Jackson
R
R
Clair
J
J
Frankenfield
D
D
D000135:Acid Phosphatase / Q000097:blood; D019386:Alendronate; D000704:Analysis of Variance; D000818:Animals; D015519:Bone Density; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism*; D002118:Calcium / Q000097:blood; D004164:Diphosphonates / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D015675:Osteocalcin / Q000097:blood; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D010052:Ovariectomy; D010215:Papio; D010281:Parathyroid Hormone / Q000097:blood; D011863:Radioimmunoassay
D004164:Diphosphonates; D010281:Parathyroid Hormone; D015675:Osteocalcin; D004958:Estradiol; D000135:Acid Phosphatase; D002118:Calcium; D019386:Alendronate